Chief & Presenting Author: Dr.Supriya Rawat

Co Author(s): Dr.Wilhemina Chauhan

Abstract

STUDY DESIGN: Hospital based prospective interventional study conducted from july 2020 to july 2022.
PURPOSE: Evaluate clinical outcome after intravitreal injection of Ranizumab in ROP in terms of regression or progression & its relation to risk factors.
METHOD: Study comprises 74 eyes of 37 patients of ROP fulfilling inclusion criteria. Intravitreaal ANTI-VEGF given under aseptic conditions. Posterior segment assessment with Indirect Ophthalmoscopy or RetCam photography.
RESULTS: Regression in 71(95.95%) eyes within 7 days & in all 74 eyes within day 14-21 .74.32 % showed regression after single dose & 25.68% with additional dose. Low gestational age & low birth weight was associated with higher recurrence.
CONCLUSION: Favourable outcome with intravitreal Ranizumab but need laser photocoagulation in few cases.